TG Therapeutics, Inc.

TGTXNASDAQ • USD
63.56 USD
↘ 0.95 (1.48%)🟢LIVE (AS OF 10:34 AM EST)
🟢Market: OPEN

TGTX is currently priced at $63.56. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". This is driven by a robust Altman Z-Score, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, TGTX trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Nov 13, 2026.

Open?$64.69
High?$65.22
Low?$63.31
Prev. Close?$64.51
Volume?245.7K
Avg. Volume?1.9M
VWAP?$64.01
Rel. Volume?0.13x
Bid / Ask
Bid?$55.24 × 100
Ask?$72.79 × 100
Spread?$17.55
Midpoint?$64.02
Valuation & Ratios
Market Cap?9.8B
Shares Out?151.1M
Float?147.3M
Float %?96.2%
P/E Ratio?91.94
P/B Ratio?17.04
EPS?$0.70
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Employees
399
Market Cap
9.8B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
1995-12-14
Address
2 GANSEVOORT STREET, 9TH FLOOR
NEW YORK, NY 10014
Phone: (212) 554-4484
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
100
Momentum?
31
Short Sent.?
39
Piotroski F-Score?4/9Mixed
Altman Z-Score?6.51Safe
Confidence?60%Moderate
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?19.53%High
Short Interest?28.8M
Days to Cover?18.9
Free Float147.3M
Avg Daily Volume1.5M
Settlement Date2026-10-30
Financial Health
Current Ratio?4.50Strong
Quick Ratio?3.75Strong
Cash Ratio?1.65Strong
Debt/Equity?1.30Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
33/100
P/E?
Peers
100
S&P
3
91.9PRICEY▾
P/B?
Peers
100
S&P
9
17.04HIGH▾
P/S?
Peers
100
S&P
7
10.86HIGH▾
P/FCF?
Peers
100
S&P
3
114.0PRICEY▾
EV/EBITDA?
Peers
100
S&P
3
52.2HIGH▾
EV/Sales?
Peers
100
S&P
9
11.21HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
63
18.5%STRONG▾
ROA?
Peers
50
S&P
58
6.7%FAIR▾
Cash Flow & Enterprise
FCF?$85.6M
Enterprise Value?$10.1B
Fundamentals ratios updated end of day